This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Robbins Umeda LLP Announces An Investigation Of Metropolitan Health Networks, Inc.









SAN DIEGO, Nov. 6, 2012 /PRNewswire/ -- Shareholder rights firm Robbins Umeda LLP has commenced an investigation into possible breaches of fiduciary duty and other violations of the law by members of the board of directors of Metropolitan Health Networks, Inc. (NYSE: MDF) in connection with their efforts to sell the company to Humana Inc. (NYSE: HUM).  Concerned shareholders who would like more information about their rights and potential remedies can contact attorney Gregory E. Del Gaizo at (800) 350-6003, info@robbinsumeda.com, or via the shareholder information form on the firm's website.

(Logo:  http://photos.prnewswire.com/prnh/20111014/ROBBINSUMEDALOGO)

On November 5, 2012, Metropolitan and Humana announced that they had entered into a definitive merger agreement under which Metropolitan will be acquired by Humana.  According to the terms of the deal, Humana will acquire Metropolitan through an all cash tender offer valued at approximately $850 million.  Metropolitan shareholders will receive $11.25 per share. The $11.25 per share offer price represents a premium of only 3.7% based on Metropolitan's closing price on November 5, 2012.  In contrast, in deals announced within the last year in the Healthcare Providers and Services sector, of which Metropolitan is a member, the average one-day premium has been 49.88%.  Further, multiple analysts have set price targets higher than the $11.25 offer price with at least one analyst from Sidoti & Company setting a price target for Metropolitan stock at $13.00 per share as recently as September 26, 2012.  The transaction is expected to close by the end of the first quarter of 2013.

Robbins Umeda LLP's investigation focuses on whether the board of directors at Metropolitan is undertaking a fair process to obtain maximum value and adequately compensate its shareholders.  On August 9, 2012, Metropolitan reported financial results for the second quarter of fiscal 2012 with revenue for the second quarter of 2012 of $193.4 million compared to $97.3 million for the second quarter of 2011, an increase of $96.1 million or 98.8%.  Metropolitan's gross profit was $28.4 million for the second quarter of 2012 compared to $16.6 million for the same quarter in 2011, an increase of $11.8 million or 71.1%.  Given these financial results, Robbins Umeda LLP is examining the board of directors' decision to sell Metropolitan now rather than allow shareholders to continue to participate in the company's continued success and future growth prospects.

Robbins Umeda LLP attorneys highlight that Metropolitan shareholders have the option to file a class action lawsuit against the company to secure the best possible price for the company's shareholders and the disclosure of material information to shareholders so they can vote on the transaction in an informed manner.

Robbins Umeda LLP is a nationally recognized leader in securities litigation and shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested. For more information, please go to http://www.robbinsumeda.com.  

Press release link: http://www.robbinsumeda.com/shareholders-rights-blog/metropolitan-health-networks/

Attorney Advertising.Past results do not guarantee a similar outcome.  

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs